Merck Stock Valuations Suggest Undervaluation, But Risks Remain

Merck's stock has experienced significant growth over the past five years, returning 141.2%. However, valuation signals are mixed, with a Discounted Cash Flow (DCF) model indicating undervaluation and market multiples showing expense.

The DCF model estimates Merck's intrinsic value to be around $233 per share, suggesting the stock is undervalued by 34.6% compared to its current price of about $118.5x P/E ratio, which is far above the pharmaceuticals industry average of 16.5x and peer group average of 30.9x.

The fair P/E ratio implied by this model is 48.8x, which is still lower than Merck's current multiple but higher than the industry benchmark.

Investors are weighing two sharply different storylines: a bull case suggesting the stock could be undervalued and a bear case indicating it may be overvalued due to patent and pricing risks.